0ACX Stock Overview
A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Centessa Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.91 |
| 52 Week High | US$18.86 |
| 52 Week Low | US$8.49 |
| Beta | 1.53 |
| 1 Month Change | -10.10% |
| 3 Month Change | -2.66% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 70.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0ACX | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -4.0% | 2.0% | 0.4% |
| 1Y | n/a | -24.1% | 3.3% |
Return vs Industry: Insufficient data to determine how 0ACX performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0ACX performed against the UK Market.
Price Volatility
| 0ACX volatility | |
|---|---|
| 0ACX Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0ACX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0ACX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 75 | Saurabh Saha | www.centessa.com |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
Centessa Pharmaceuticals plc Fundamentals Summary
| 0ACX fundamental statistics | |
|---|---|
| Market cap | US$2.16b |
| Earnings (TTM) | -US$161.26m |
| Revenue (TTM) | US$6.85m |
314.6x
P/S Ratio-13.4x
P/E RatioIs 0ACX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0ACX income statement (TTM) | |
|---|---|
| Revenue | US$6.85m |
| Cost of Revenue | US$0 |
| Gross Profit | US$6.85m |
| Other Expenses | US$168.12m |
| Earnings | -US$161.26m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,353.20% |
| Debt/Equity Ratio | 15.2% |
How did 0ACX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 14:38 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Centessa Pharmaceuticals plc is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |